MAP3K7 and Alzheimer disease: Our findings identify Metformin as a novel inducer of CMA, discover the first reported mechanism of CMA activation downstream of TAK1-IKKα/β signaling, and suggest that CMA activation to degrade Aβ could be a putative therapeutic strategy for AD.